CLASS ACTION UPDATE for AMZN, SPRO and IONQ: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders

NEW YORK, NY / ACCESSWIRE / June 3, 2022 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.

AMZN Shareholders Click Here: https://www.zlk.com/pslra-1/amazon-com-inc-loss-submission-form?prid=28108&wire=1
SPRO Shareholders Click Here: https://www.zlk.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=28108&wire=1
IONQ Shareholders Click Here: https://www.zlk.com/pslra-1/ionq-inc-loss-submission-form?prid=28108&wire=1

* ADDITIONAL INFORMATION BELOW *

Amazon.com, Inc. AMZN

AMZN Lawsuit on behalf of: investors who purchased February 1, 2019 - April 5, 2022
Lead Plaintiff Deadline : July 5, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/amazon-com-inc-loss-submission-form?prid=28108&wire=1

According to the filed complaint, during the class period, Amazon.com, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Amazon engaged in anticompetitive conduct in its private-label business practices, including giving Amazon products preference over those of its competitors and using third-party sellers' non-public data to compete with them; (ii) the foregoing exposed Amazon to a heightened risk of regulatory scrutiny and/or enforcement actions; (iii) Amazon's revenues derived from its private-label business were in part the product of impermissible conduct and thus unsustainable; and (iv) as a result, the defendants' public statements throughout the class period were materially false and/or misleading.

Spero Therapeutics, Inc. SPRO

SPRO Lawsuit on behalf of: investors who purchased October 28, 2021 - May 2, 2022
Lead Plaintiff Deadline : July 25, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/spero-therapeutics-inc-loss-submission-form?prid=28108&wire=1

According to the filed complaint, during the class period, Spero Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

IonQ, Inc. IONQ

IONQ Lawsuit on behalf of: investors who purchased March 30, 2021 - May 2, 2022
Lead Plaintiff Deadline : August 1, 2022
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/ionq-inc-loss-submission-form?prid=28108&wire=1

According to the filed complaint, during the class period, IonQ, Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) IonQ had not yet developed a 32-qubit quantum computer; (2) the Company's 11-qubit quantum computer suffered from significant error rates, rendering it useless; (3) IonQ's quantum the computer is not sufficiently reliable, so it is not accessible despite being available through major cloud providers; (4) a significant portion of IonQ's revenue was derived from improper roundtripping transactions with related parties; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were the materially misleading and/or lacked a reasonable basis.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Eduard Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP